Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine.
Most malariologists believe that optimal malaria vaccines will induce protective immune responses against different stages of the parasite's life cycle. A multiple antigen peptide (MAP) vaccine based on the Plasmodium yoelii circumsporozoite protein (PyCSP) protects mice against sporozoite challenge by inducing antibodies that prevent sporozoites from invading hepatocytes. A purified recombinant protein vaccine based on the P. yoelii merozoite surface protein-1 (PyMSP-1) protects mice against challenge with infected erythrocytes, presumably by inducing antibodies against the erythrocytic stage of the parasite. We now report studies designed to determine if the PyMSP-1 vaccine protects against challenge with sporozoites, the stage encountered in the field, and if immunization with a combination of the PyCSP and PyMSP-1 vaccines provides additive or synergistic protection against sporozoite challenge. In two experiments, using TiterMax or Ribi R-700 as adjuvant, 3 of 19 mice immunized with the PyMSP-1 vaccine were completely protected against sporozoite challenge. The remaining mice had significantly delayed onset and lower levels of peak parasitemia than did control mice (11.1 +/- 2.8% vs. 36.7 +/- 1.6% in experiment #2, P < 0.01). Immunization with the combination vaccine reduced by approximately 50% the level of antibodies induced to PyCSP and PyMSP-1, as compared to that induced by the individual components. However, in two experiments, there was evidence of additive protection. Six of 19 (31.6%) immunized with the PyCSP vaccine, 3 of 19 (15.8%) immunized with the PyMSP-1 vaccine, and 10 of 19 (52.6%) immunized with the combination were completely protected against sporozoit challenge. This modest increase in protection in the combination group may be a reflection of additive anti-PyCSP and anti-PyMSP-1 immunity, since mice in the combination group had diminished levels of antibodies to each components. These studies indicate that considerable work may be required to optimize the construction, delivery, and assessment of multi-stage malaria vaccines.
Wang
R
R
Malaria Program, Naval Medical Research Institute, Bethesda, MD 20889-5607, USA.
Charoenvit
Y
Y
Daly
T M
TM
Long
C A
CA
Corradin
G
G
Hoffman
S L
SL
D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis; D017358:Cell Wall Skeleton / Q000494:pharmacology; D003311:Cord Factors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015151:Immunoblotting; D007132:Immunoglobulin Isotypes / Q000032:analysis; D008050:Lipid A / Q000031:analogs & derivatives / Q000494:pharmacology; D008288:Malaria / Q000276:immunology* / Q000517:prevention & control*; D020066:Merozoite Surface Protein 1; D051379:Mice; D008807:Mice, Inbred BALB C; D018512:Parasitemia / Q000276:immunology; D010967:Plasmodium yoelii / Q000276:immunology*; D011060:Poloxalene / Q000494:pharmacology; D011498:Protein Precursors / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology; D014611:Vaccination; D017778:Vaccines, Combined / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D000913:Antibodies, Protozoan; D017358:Cell Wall Skeleton; D003311:Cord Factors; D007132:Immunoglobulin Isotypes; D008050:Lipid A; D020066:Merozoite Surface Protein 1; D011498:Protein Precursors; D015800:Protozoan Proteins; C075897:Ribi adjuvant; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic; C086752:TiterMax; D011060:Poloxalene